Andrä Claudia, Klein Alexander, Dürr Hans Roland, Rauch Josefine, Lindner Lars Hartwin, Knoesel Thomas, Angele Martin, Baur-Melnyk Andrea, Belka Claus, Roeder Falk
Department of Radiation Oncology, University Hospital of Munich (LMU), Marchioninistr. 15, 81377, Munich, Germany.
Department of Orthopedics, University Hospital of Munich (LMU), Munich, Germany.
Strahlenther Onkol. 2017 Aug;193(8):604-611. doi: 10.1007/s00066-017-1109-x. Epub 2017 Feb 22.
To report our experience with EBRT combined with limb-sparing surgery in elderly patients (>70 years) with primary extremity soft tissue sarcomas (STS).
Retrospectively analyzed were 35 patients (m:f 18:17, median 78 years) who all presented in primary situation without nodal/distant metastases (Charlson score 0/1 in 18 patients; ≥2 in 17 patients). Median tumor size was 10 cm, mainly located in lower limb (83%). Stage at presentation (UICC7th) was Ib:3%, 2a:20%, 2b:20%, and 3:57%. Most lesions were high grade (97%), predominantly leiomyosarcoma (26%) and undifferentiated pleomorphic/malignant fibrous histiocytoma (23%). Limb-sparing surgery was preceded (median 50 Gy) or followed (median 66 Gy) by EBRT.
Median follow-up was 37 months (range 1-128 months). Margins were free in 26 patients (74%) and microscopically positive in 9 (26%). Actuarial 3‑ and 5‑year local control rates were 88 and 81% (4 local recurrences). Corresponding rates for distant control, disease-specific survival, and overall survival were 57/52%, 76/60%, and 72/41%. The 30-day mortality was 0%. Severe postoperative complications were scored in 8 patients (23%). Severe acute radiation-related toxicity was observed in 2 patients (6%). Patients with Charlson score ≥2 had a significantly increased risk for severe postoperative complications and acute radiation-related side effects. Severe late toxicities were found in 7 patients (20%), including fractures in 3 (8.6%). Final limb preservation rate was 97%.
Combination of EBRT and limb-sparing surgery is feasible in elderly patients with acceptable toxicities and encouraging but slightly inferior outcome compared to younger patients. Comorbidity correlated with postoperative complications and acute toxicities. Late fracture risk seems slightly increased.
报告我们对老年(>70岁)原发性肢体软组织肉瘤(STS)患者采用外照射放疗(EBRT)联合保肢手术的经验。
回顾性分析35例患者(男:女为18:17,中位年龄78岁),所有患者均为初诊,无区域/远处转移(18例患者Charlson评分为0/1;17例患者≥2)。肿瘤中位大小为10 cm,主要位于下肢(83%)。初诊时分期(国际抗癌联盟第7版)为Ib期:3%,2a期:20%,2b期:20%,3期:57%。大多数病变为高级别(97%),主要为平滑肌肉瘤(26%)和未分化多形性/恶性纤维组织细胞瘤(23%)。保肢手术前(中位剂量50 Gy)或后(中位剂量66 Gy)进行EBRT。
中位随访时间为37个月(范围1 - 128个月)。26例患者(74%)切缘阴性,9例(26%)镜下阳性。3年和5年局部控制率分别为88%和81%(4例局部复发)。远处控制、疾病特异性生存和总生存的相应率分别为57/52%、76/60%和72/41%。30天死亡率为0%。8例患者(23%)出现严重术后并发症。2例患者(6%)观察到严重急性放疗相关毒性。Charlson评分≥2的患者严重术后并发症和急性放疗相关副作用的风险显著增加。7例患者(20%)出现严重晚期毒性,包括3例骨折(8.6%)。最终保肢率为97%。
EBRT联合保肢手术在老年患者中是可行的,毒性可接受,与年轻患者相比,结果令人鼓舞但略逊一筹。合并症与术后并发症和急性毒性相关。晚期骨折风险似乎略有增加。